Latest Close
₹1,358.00
+0.59%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹1,411.80
200 DMA
₹1,378.33
1 year gain / loss
−₹182.10(-11.82%)
₹1,540.10 → ₹1,358.00· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-10-31 · Financial period Jun 2026 · Consolidated figures where available
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
Market Cap
₹1,11,486.14 Cr
P/E
39.06×
Sector -38.72× · above
P/B
3.15×
Sector 4.11× · below
EV / EBITDA
20.71×
Sector 22.21× · below
ROE
8.18%
Sector 0.31%
ROCE
10.80%
Sector 6.48%
ROA
6.60%
Sector -17.12%
Cash Flow / Profit
1.02×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 7,330.18 +9.6% | 1,081.93 | 787.1 +43.1% |
| Mar 2026 | 6,689.36 -8.1% | 707.06 | 550.11 -18.4% |
| Dec 2025 | 7,280.82 -7.3% | 893.11 | 674.56 -50.1% |
| Sep 2025 | 7,858.39 | 1,853.53 | 1,353.07 |
Dividend
05 Jun 2026 · ₹13